These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39226499)

  • 1. US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease.
    Beinfeld MT; LaMountain F; Wong W; Kim E; Chambers JD
    Health Aff (Millwood); 2024 Sep; 43(9):1290-1295. PubMed ID: 39226499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilar underutilization alone does not foretell a broken biologics market.
    LaMountain F; Beinfeld MT; Wong W; Kim E; Chambers JD
    Health Aff Sch; 2024 Jul; 2(7):qxae090. PubMed ID: 39071106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: How Can Payers Get Long-Term Savings?
    Mestre-Ferrandiz J; Towse A; Berdud M
    Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2-Biosimilar and Originator Etanercept in the Outpatient Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):299-306. PubMed ID: 30945206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars And Follow-On Products In The United States: Adoption, Prices, And Users.
    Stern AD; Chen JL; Ouellet M; Trusheim MR; El-Kilani Z; Jessup A; Berndt ER
    Health Aff (Millwood); 2021 Jun; 40(6):989-999. PubMed ID: 34097520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
    Dutta B; Huys I; Vulto AG; Simoens S
    BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
    Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share.
    Chen AJ; Kaiser KM; Gascue L; Manetas MA; Van Nuys K
    Health Aff (Millwood); 2023 Jun; 42(6):779-784. PubMed ID: 37276475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
    Yu T; Jin S; Li C; Chambers JD; Hlávka JP
    BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
    Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
    BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it.
    Mehr SR
    J Manag Care Spec Pharm; 2024 Jun; 30(6):600-603. PubMed ID: 38824633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
    Horn DM; Alpert AE; Duggan MG; Garcia NA; Jacobson M
    JCO Oncol Pract; 2023 Apr; 19(4):e476-e483. PubMed ID: 36638330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea.
    Lee HJ; Han E; Kim H
    Appl Health Econ Health Policy; 2020 Aug; 18(4):557-566. PubMed ID: 31930450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar competition: Early learning.
    Frank RG; Shahzad M; Kesselheim AS; Feldman W
    Health Econ; 2022 Apr; 31(4):647-663. PubMed ID: 35023225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.